Rasio cepet: Vertex Pharmaceuticals (VRTX)

Vertex Pharmaceuticals relies on a stable cash flow due to its monopoly in cystic fibrosis therapy. The GURU.Markets platform displays a historical snapshot of immediate liquidity, where 2.62 reflects the latest value of the metric. High R&D expenditures and stringent FDA oversight create significant barriers, while expansion into the treatment of genetic blood pathologies extends the company's market influence.

Vertex Pharmaceuticals prioritizes the development of critical orphan drugs, which requires high financial stability to support R&D. An analysis of the acid-test ratio demonstrates the company's ability to meet short-term obligations without liquidating inventory, relying solely on cash and accounts receivable. This metric excludes illiquid assets, revealing the business's actual margin of safety. A consistently high ratio confirms effective capital management and minimizes the risk of credit default.